Zum Hauptinhalt springen

The possible mechanisms of action of progestins on endometrial adenocarcinoma.

Anderson, DG
In: American journal of obstetrics and gynecology, Jg. 113 (1972-05-15), Heft 2, S. 195-211
academicJournal

Titel:
The possible mechanisms of action of progestins on endometrial adenocarcinoma.
Autor/in / Beteiligte Person: Anderson, DG
Zeitschrift: American journal of obstetrics and gynecology, Jg. 113 (1972-05-15), Heft 2, S. 195-211
Veröffentlichung: <2005->: New York : Elsevier ; <i>Original Publication</i>: St. Louis., 1972
Medientyp: academicJournal
ISSN: 0002-9378 (print)
DOI: 10.1016/0002-9378(72)90769-7
Schlagwort:
  • 17-Hydroxycorticosteroids urine
  • 17-Ketosteroids urine
  • Adenocarcinoma pathology
  • Aged
  • Biopsy
  • Blood Cell Count
  • Blood Protein Electrophoresis
  • Endometrium pathology
  • Estrogens urine
  • Female
  • Follicle Stimulating Hormone antagonists & inhibitors
  • Gonadotropins, Pituitary antagonists & inhibitors
  • Humans
  • Immunity drug effects
  • Luteinizing Hormone antagonists & inhibitors
  • Lymphocytes
  • Medroxyprogesterone pharmacology
  • Middle Aged
  • Palliative Care
  • Pregnanediol urine
  • Remission, Spontaneous
  • Time Factors
  • Adenocarcinoma drug therapy
  • Medroxyprogesterone therapeutic use
  • Uterine Neoplasms drug therapy
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article
  • Language: English
  • [Am J Obstet Gynecol] 1972 May 15; Vol. 113 (2), pp. 195-211.
  • MeSH Terms: Adenocarcinoma / *drug therapy ; Medroxyprogesterone / *therapeutic use ; Uterine Neoplasms / *drug therapy ; 17-Hydroxycorticosteroids / urine ; 17-Ketosteroids / urine ; Adenocarcinoma / pathology ; Aged ; Biopsy ; Blood Cell Count ; Blood Protein Electrophoresis ; Endometrium / pathology ; Estrogens / urine ; Female ; Follicle Stimulating Hormone / antagonists & inhibitors ; Gonadotropins, Pituitary / antagonists & inhibitors ; Humans ; Immunity / drug effects ; Luteinizing Hormone / antagonists & inhibitors ; Lymphocytes ; Medroxyprogesterone / pharmacology ; Middle Aged ; Palliative Care ; Pregnanediol / urine ; Remission, Spontaneous ; Time Factors
  • Contributed Indexing: Indexing Agency: PIP Local ID #: 720743. Indexing Agency: POP Local ID #: 00003321. ; Keywords: Biology; Cancer; Clinical Research*; Contraception; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents, Progestin--therapeutic use; Contraceptive Agents--therapeutic use; Contraceptive Effectiveness; Cytologic Effects; Depo-provera--therapeutic use*; Diseases; Endometrial Cancer*; Evaluation*; Family Planning; Immunity; Immunological Effects*; Injectables; Medroxyprogesterone Acetate--therapeutic use*; Neoplasms; Physiology; Research Methodology; Steroid Metabolic Effects; Use-effectiveness* ; Local Abstract: [PIP] To investigate the effect of medroxyprogesterone acetate therapy upon the immune response and endogenous status of patients with primary or recurrent endometrial adenocarcinoma, 8 patients were treated with progestin therapy as inpatients for 33-80 days. Patients were studied intermittently for up to 72 months. Serum protein electrophoresis during treatment showed no change in protein pattern. In all 8 patients, there was a suppression of pituitary gonadotrophin. There was no evidence that the adenocarcinomas were suppressed by either an immunologic mechanism or by the variation in endogenous hormone production. Investigation should be continued to study the effects of medroxyprogesterone acetate on the cellular level.
  • Substance Nomenclature: 0 (17-Hydroxycorticosteroids) ; 0 (17-Ketosteroids) ; 0 (Estrogens) ; 0 (Gonadotropins, Pituitary) ; 9002-67-9 (Luteinizing Hormone) ; 9002-68-0 (Follicle Stimulating Hormone) ; HSU1C9YRES (Medroxyprogesterone) ; JR3JD1Y22C (Pregnanediol)
  • Entry Date(s): Date Created: 19720515 Date Completed: 19720721 Latest Revision: 20190615
  • Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -